Cargando…

Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients

BACKGROUND: The efficacy of statin therapy may be lost or vary with reduction in compliance and intensity of statin therapy. OBJECTIVE: To study and correlate the quantitative effect of compliance on lipid profile and 3-hydroxyl-3-methylglutaryl coenzyme A reductase (HMGCoA-R) levels in dyslipidemic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grover, Abhinav, Rehan, Harmeet Singh, Gupta, Lalit Kumar, Yadav, Madhur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319005/ https://www.ncbi.nlm.nih.gov/pubmed/28228309 http://dx.doi.org/10.1016/j.ihj.2016.07.007

Ejemplares similares

Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels
por: Grover, Abhinav, et al.
Publicado: (2020)

Correction: Self-reported Morisky Eight-item Medication Adherence Scale for Statins Concords with the Pill Count Method and Correlates with Serum Lipid Profile Parameters and Serum HMGCoA Reductase Levels
por: Grover, Abhinav, et al.
Publicado: (2023)

Inhibition of HMGCoA reductase by simvastatin protects mice from injurious mechanical ventilation
por: Manitsopoulos, Nikolaos, et al.
Publicado: (2015)

Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase
por: Kato, S, et al.
Publicado: (2010)

Functional food mixtures: Inhibition of lipid peroxidation, HMGCoA reductase, and ACAT2 in hypercholesterolemia‐induced rats
por: Mohd Rosmi, Noor Syafiqa Aqila, et al.
Publicado: (2020)

Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas
por: de Groot, Evelyn, et al.
Publicado: (2022)

Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients
por: Kumar, Manoj, et al.
Publicado: (2018)

Synergic effect of Eicosapentaenoic acid and Lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells
por: Notarnicola, Maria, et al.
Publicado: (2010)

Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment
por: AYDIN, Kadriye, et al.
Publicado: (2019)

The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients
por: Nartea, Roxana, et al.
Publicado: (2023)

Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients
por: Bener, Abdulbari, et al.
Publicado: (2014)

Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C
por: Rehan, Harmeet Singh, et al.
Publicado: (2014)

Serum lysophospholipid levels are altered in dyslipidemic hamsters
por: Suárez-García, Susana, et al.
Publicado: (2017)

Self-reported Morisky eight item medication adherence scale is a reliable and valid measure of compliance to statins in hyperlipidemic patients in India
por: Grover, Abhinav, et al.
Publicado: (2020)

Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients
por: Hadigal, Sanjay, et al.
Publicado: (2014)

Correlation of long-term glycemic control as measured by glycated hemoglobin with serum angiopoietin-like 6 protein levels in type 2 diabetes mellitus patients
por: Sharma, Vikaas, et al.
Publicado: (2017)

A Scoping Review on the Reported Evidence and Gaps of the Risk of Diabetes in Dyslipidemic Patients under Statin Therapy
por: Needamangalam Balaji, Jyotsna, et al.
Publicado: (2022)

The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol
por: Fortes, Patricia M., et al.
Publicado: (2018)

Diversity of Genotype and Mode of Spread of Hepatitis C Virus in Northern India
por: Rehan, Harmeet S., et al.
Publicado: (2011)

Dyslipidemic drugs in metabolic syndrome
por: Siddiqi, Sheelu S., et al.
Publicado: (2013)

Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis
por: Alvarez-Jimenez, Laura, et al.
Publicado: (2022)

Sphingolipid serum profiling in vitamin D deficient and dyslipidemic obese dimorphic adults
por: Al-Daghri, Nasser M., et al.
Publicado: (2019)

Cardiac Mitochondria Dysfunction in Dyslipidemic Mice
por: Braczko, Alicja, et al.
Publicado: (2022)

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
por: Teramoto, Tamio, et al.
Publicado: (2012)

Mass-Spectrometry-Based Lipidomics Discriminates Specific Changes in Lipid Classes in Healthy and Dyslipidemic Adults
por: Sánchez-Vinces, Salvador, et al.
Publicado: (2023)

Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C Infection: An exploratory study
por: Rehan, Harmeet Singh, et al.
Publicado: (2015)

Pharmacokinetic interaction of garlic and atorvastatin in dyslipidemic rats
por: Reddy, G. Dilip, et al.
Publicado: (2012)

Potential benefits of L. acidophilus in dyslipidemic rats
por: Reamtong, Onrapak, et al.
Publicado: (2021)

Addressing dyslipidemic risk beyond LDL-cholesterol
por: Tall, Alan R., et al.
Publicado: (2022)

Publisher Correction: Sphingolipid serum profiling in vitamin D deficient and dyslipidemic obese dimorphic adults
por: Al-Daghri, Nasser M., et al.
Publicado: (2020)

Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study
por: Derosa, Giuseppe, et al.
Publicado: (2019)

Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs
por: Kumar, Sudhir, et al.
Publicado: (2017)

The effect of dyslipidemic drugs on mortality: A meta-analysis
por: Jain, Shuchi, et al.
Publicado: (2009)

Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome
por: Lemche, A. V., et al.
Publicado: (2016)

Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice
por: Puato, Massimo, et al.
Publicado: (2021)

LDL Particle Size and Reactive Oxygen Metabolites in Dyslipidemic Patients
por: Kotani, Kazuhiko, et al.
Publicado: (2012)

Grape juice attenuates left ventricular hypertrophy in dyslipidemic mice
por: Martins, Ângela Maria, et al.
Publicado: (2020)

Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment
por: Guasti, Luigina, et al.
Publicado: (2016)

Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
por: Werba, José P., et al.
Publicado: (2019)

Synergetic Action of Forskolin and Mevastatin Induce Normalization of Lipids Profile in Dyslipidemic Rats through Adenosine Monophosphate Kinase Upregulation
por: Abdelazim, Aaser M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0u3n3mrr1v9kum19dnn7i0icf